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REVIEW
Abstract: COPD is a major cause of mortality and morbidity worldwide with an estimated 
2.75 million deaths in 2000 (fourth leading cause of death). In addition to the considerable 
morbidity and mortality associated with COPD, this disease incurs signiﬁ  cant healthcare and 
societal costs. Current COPD guidelines acknowledge that the following can improve COPD 
mortality: smoking cessation; long-term oxygen therapy; and lung volume reduction surgery 
in small subsets of COPD patients. To date, no randomized controlled trials have demonstrated 
an effect of pharmacological treatment on mortality, although several observational studies 
suggest that both long-acting bronchodilators and inhaled corticosteroids may provide a survival 
beneﬁ  t. The possibility that these treatments reduce mortality is being investigated in ongoing 
large-scale clinical trials.
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Introduction
COPD represents a signiﬁ  cant and growing healthcare concern as a leading cause of 
morbidity and mortality worldwide. According to the Global Burden of Disease (GBD) 
study 2000, COPD was responsible for an estimated 2.75 million deaths worldwide 
(Lopez et al 2006), half of which were documented in the Western Paciﬁ  c region. 
An earlier study estimated that 2.2 million deaths worldwide were caused by COPD 
(Murray and Lopez 1997a). In the USA, COPD is currently the fourth leading cause of 
death and is projected to be the third by 2020 (US Department of Health and Human 
Services 2003).
According to the American Thoracic Society/European Respiratory Society 
(ATS/ERS) guidelines, COPD is characterized by airﬂ  ow limitation that is not fully 
reversible. This airﬂ  ow limitation is usually progressive and is associated with an 
abnormal inﬂ  ammatory response of the lungs to noxious particles or gases. Although 
COPD predominantly affects the lungs, it is also associated with signiﬁ  cant systemic 
consequences. Important symptoms of COPD range from chronic cough and sputum 
production to dyspnea. The single most important risk factor is a history of exposure 
to tobacco smoke; other important factors include occupational exposure to dusts and 
chemicals, lower socio-economic status, and genetic predisposition. 
A diagnosis of COPD should be considered if any of these key indicators are 
present and conﬁ  rmed by spirometry. Both the ATS/ERS and the Global Initiative 
for Obstructive Lung Disease (GOLD) guidelines state that a FEV1/FVC ratio <0.7 
conﬁ  rms the diagnosis of COPD. It should be noted that there is a decline in 
FEV1/FVC ratio with age and it is possible that some older, healthy individuals 
may be incorrectly diagnosed as having COPD (Crapo and Morris 1989; Hardie 
et al 2002; Barreiro and Perillo 2004); however, this issue is subject to controversy 
and data from cohort studies are not yet available. Furthermore, patients classiﬁ  ed 
as GOLD stage 0 or stage 1 may have FEV1 ≥80% of predicted and are deﬁ  ned as 
either being at risk for, or having, mild COPD (Table 1) (Celli et al 2004; GOLD 
2005). Disease stage is regarded as a general indication of COPD severity which, 
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together with other information such as presence and 
severity of symptoms, frequency of exacerbations, presence 
of comorbid conditions, and history of asthma or exposure 
to risk factors, determines the most optimal approach to 
management. 
COPD runs an insidious course and is often undiagnosed 
for many years, particularly in its early stages (Anto et al 
2001). The progression of the disease varies by COPD 
phenotype, a concept that is currently poorly understood. 
From the early stages of COPD and as the disease 
develops, chronic inﬂ  ammation of the airways and lung 
parenchyma result in progressive airﬂ  ow limitation with 
an accelerated rate of decline in FEV1 and increased 
hyperinﬂ  ation, which cause breathing difﬁ  culties and 
reduce exercise tolerance (Hogg et al 2004; Sutherland 
and Cherniack 2004). Pathological changes are observed 
in the central and peripheral airways, the parenchyma, 
and the pulmonary vasculature. In addition to inﬂ  amma-
tion, an imbalance of proteinases and antiproteinases in 
the lungs and oxidative stress are also important in the 
pathogenesis of COPD (Repine et al 1997). These patho-
logical changes result in the well recognized physiologi-
cal abnormalities of COPD: mucous hypersecretion and 
ciliary dysfunction; airﬂ  ow limitation and hyperinﬂ  ation; 
destruction of alveoli and emphysema; gas exchange 
abnormalities; pulmonary hypertension; and various sys-
temic effects (Matsuba et al 1989; O’Donnell et al 2001; 
Hogg et al 2004).
The clinical manifestations of COPD are generally well 
understood, but the underlying pathogenesis of COPD is 
less well established. Even less certain are the true extent 
and burden of mortality associated with COPD, and whether 
this burden can be altered by non-pharmacological or 
pharmacological approaches. To address this knowledge 
gap, this paper reviews the published data on the mortality 
burden of COPD and considers the data describing the 
impact of currently available therapeutic interventions on 
mortality.
Causes of death in COPD
Despite the high global death toll and cost of COPD, we are 
still learning more about the mechanisms that cause death 
in patients with COPD. Clinical trial data and extensive 
review of clinical patients show that a range of factors 
including lung failure, cor pulmonale, cardiovascular 
disease, and lung cancer are all important contributors 
to death in patients with COPD (Braghiroli et al 1997; 
Zielinski et al 1997; Waterhouse et al 1999; Anthonisen 
et al 2005). Large population-based studies have also 
reported on the causes of death in COPD patients. Hansell 
et al (2003a) recently analyzed death certiﬁ  cate data in 
England and Wales between 1993 and 1999 that included 
more than 300 000 deaths in patients with COPD. The aims 
of the study were to quantify the extent to which obstruc-
tive lung disease (OLD) contributed to death and to better 
characterize speciﬁ  c causes of death in OLD patients. The 
authors noted that approximately 60% of deaths in COPD 
patients were attributed to COPD itself, while 25% of the 
patients died as a result of diseases of the circulatory system 
and more than 5% of deaths were attributed to neoplasms 
(Hansell et al 2003a).
In contrast, data from Finland gathered over a 20-year 
period indicated that coronary heart disease and other 
circulatory diseases were the primary causes of death 
in patients with COPD (37.3%), followed by COPD 
itself (30.2%), lung cancer (12.1%), and other malignan-
cies (7.9%) (Vilkman et al 1997; Keistinen et al 1998). 
Taken together, these data indicate that COPD itself and 
other respiratory causes, cardiovascular disease, and lung 
cancer are the most important causes of death in COPD 
patients.
Table 1 Classiﬁ  cation of severity of COPD using GOLD criteria (GOLD 2005)
Stage    Characteristic 
   FEV1/FVC
a   FEV1, % predicted
a   Chronic  symptoms
b 
0 (at risk)   Normal   Normal   + 
I (mild COPD)   <70%    ≥80%   ± 
II (moderate COPD)   <70%   <80%  but  ≥50%   ± 
III (severe COPD)   <70%   <50%  but  ≥30%   ± 
IV (very severe COPD)   <70%    <30%; or <50% with chronic respiratory failure
c   ± 
aClassiﬁ  cation based on post-bronchodilator FEV1.
bCough, sputum production.
cArterial partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mmHg) with or without arterial partial pressure of CO2 (PaCO2) greater than 6.7 kPa (50 mmHg) while 
breathing air at sea level.
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity.International Journal of COPD 2006:1(3) 221
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A growing body of trial data suggests that systemic 
and pulmonary inﬂ  ammation may provide a mechanistic 
link between COPD, cardiovascular disease, lung cancer 
and other comorbid conditions (Mukhopadhyay et al 
1995; Wedzicha et al 2000; Sin and Man 2003a; Wright 
and Christman 2003; Gan et al 2004; Greten et al 2004; 
Hogg et al 2004; Pikarsky et al 2004). COPD has been 
identiﬁ  ed as a signiﬁ  cant risk factor for death in patients 
with cardiac disease in two studies involving a total 
of 16 000 patients (Berger et al 2004; Curkendall et al 
2004). Similarly, COPD was identiﬁ  ed as an important 
risk factor for death in patients with lung cancer (Sekine 
et al 2002).
The burden of COPD mortality
While there is a considerable body of data concerning the 
number of deaths attributed each year to COPD throughout 
the developed world, particularly for the USA, there 
is a paucity of data for developing world regions. The 
availability of accurate epidemiological data for COPD 
mortality is hampered by the expense involved in collecting 
and collating the information, misclassiﬁ  cation of cause of 
death by attributing COPD-related deaths to other causes, or 
under-diagnosis; all of these factors under-estimate the true 
burden of COPD mortality.
Misclassiﬁ  cation potentially omits large categories of 
patients with COPD by focusing only on chronic bronchitis 
and emphysema (ICD [International Classification of 
Disease] codes 491–492). One of the largest categories of 
COPD mortality, ICD 496 (chronic airway obstruction not 
elsewhere classiﬁ  ed) has previously not been consistently 
included in the World Health Organization (WHO) estimates 
of COPD mortality, leading to a potential under-estimation of 
COPD deaths (European Respiratory Society and European 
Lung Foundation 2003).
Another possible source of COPD death under-estimation 
is provided by evidence from asthma mortality reports. 
There are strong data that many deaths attributed to asthma, 
particularly in patients aged over 65 years, are due to misclas-
siﬁ  cation of other respiratory diseases as asthma (Jenkins et 
al 1992; Smyth et al 1996; Reid et al 1998). For example, in 
the study by Reid and colleagues, based on death certiﬁ  cates 
in northern England, COPD was considered to be the true 
cause of 28 of the 55 deaths in which asthma was certiﬁ  ed as 
the direct cause. Such “diagnostic transfer” over-represents 
asthma-related deaths and under-represents COPD-related 
deaths. Finally, difﬁ  culties in verifying death certiﬁ  cates 
and disease coding practices are a considerable potential 
problem in international mortality studies that include data 
from diverse national sources. 
In general, COPD is under-diagnosed, even in 
developed countries (Mannino et al 2000). Published data 
probably under-estimate COPD deaths due to misclassiﬁ  -
cation of cause of death due to attributing COPD-related 
deaths to other causes (Mannino et al 1997, 2003), or 
reliance only upon underlying causes of death and failure 
to consider accompanying diagnoses of COPD on death 
certiﬁ  cates (Hansell et al 2003b). The WHO previously 
published mortality rates for the combined category of 
“bronchitis, emphysema and asthma” (ICD codes 490–493), 
which omits the largest category of COPD mortality (ICD 
code 519.3 in the eighth revision and ICD code 496 in the 
ninth revision). As a result there may be considerable under-
estimation of the scale of COPD deaths (Loddenkemper 
et al 2003).
Despite these challenges, however, a number of large 
national and international surveys describing COPD mortal-
ity have been published.
Global data
The GBD study for 1990 (Murray and Lopez 1997a, 1997b, 
1997c) and the recent update for 2000 (Lopez et al 2006) are 
important sources of worldwide data for COPD mortality. 
The original GBD study accessed various national and 
international data sources and requested expert opinion to 
estimate worldwide and regional cause-of-death patterns 
in 1990 for more than 100 causes of death, including 
COPD. In 1990, 2 211 000 deaths were attributed to COPD, 
representing 4.4% of all deaths recorded and making COPD 
then the sixth leading cause of worldwide mortality. The 
recent update of the GBD study shows 2.7 million deaths 
attributed to COPD in 2000 (4.8% of all deaths), making it 
the ﬁ  fth leading cause of death worldwide after ischemic 
heart disease, cerebrovascular disease, lower respiratory 
tract infections, and human immunodeﬁ  ciency virus (HIV)/
acquired immunodeficiency syndrome (AIDS). Half of 
these deaths occurred in the Western Paciﬁ  c region and the 
majority of these in China, where the incidence of COPD 
among subjects aged ≥60 years is 2–3 times higher than in 
other WHO regions. The updated report also shows about 
400 000 deaths attributed to COPD each year in industrialized 
countries. However, the authors note that the 2000 data may 
still represent an under-estimate of the actual toll of COPD 
deaths. Table 2 shows the estimated COPD deaths by WHO 
region for 2002 (Lopez et al 2006).International Journal of COPD 2006:1(3) 222
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The WHO World Health Report, 2002, estimated that 
global mortality from COPD was 44.2/100 000 population 
(WHO 2002), with mortality highest in the Western Paciﬁ  c 
region (79.8/100 000 population). Mortality due to COPD has 
been projected to rise to 4.5 million deaths in 2020, based 
upon the GBD data, with COPD by then the third leading 
cause of death (Murray and Lopez 1997a).
US data
As with the global data, US mortality data show a marked 
increase in COPD mortality over recent decades, with a 
163% increase in the age-adjusted COPD mortality rate 
from 1965 to 1998, to approximately 120 000 deaths per 
year by 2000 (Pauwels and Rabe 2004; GOLD 2005). 
These increases are particularly striking in light of the 
decreases in age-adjusted death rates for all other major 
causes of mortality (Figure 1). The most recent assess-
ment speciﬁ  c to COPD mortality in the USA was reported 
in November 2004 by the American Lung Association 
(ALA) (ALA 2004), which included an analysis of data 
from 1979 to 2002 collected from US national surveys 
and statistics on mortality attributable to COPD. Age-
adjusted death rates show an almost two-fold increase 
in COPD mortality from 24.2 per 100 000 population in 
1979 to 42 deaths per 100 000 population in 2002. The 
overall mortality rate associated with COPD increased by 
67% from 1980 to approximately 119 000 deaths in 2000 
(Mannino et al 2002). Another important source of infor-
mation on US mortality trends, the National Institutes of 
Health National Heart, Lung and Blood Institute (NHLBI) 
Morbidity and Mortality Chart Book on Cardiovascular, 
Lung and Blood Diseases, 2004 edition ranked COPD as 
the fourth leading cause of death in the USA for both men 
and women, including 125 500 deaths in 2002 for both 
genders (NHLBI 2004). 
European data
The European Lung White Book, a collaborative project 
published by the ERS and the European Lung Foundation, 
is the first comprehensive survey on respiratory health 
in Europe. Estimates based on 2004 WHO data indicate 
approximately 260 000 deaths due to COPD in 2002 (WHO 
2004). This represents 2.7% of deaths from all causes, 3.3% 
of all deaths in European men, and 2.1% of all deaths in 
European women. WHO World Health Statistics Annual 
age-adjusted mortality data for men and women aged 
35–74 years in 25 industrialized countries are shown in 
Figure 2 (Hurd 2000).
Encouraging data indicating a fall in overall COPD-
related mortality have emerged from the UK and Lithuania. 
Since 1995, the COPD mortality rates in the UK and other 
countries, including the USA and Canada, have converged. A 
recent analysis using a Bayesian age-period-cohort method to 
project COPD mortality for the period 2000–2009 in England 
and Wales predicts a median fall in mortality rates of 24% 
for males (90% credible intervals –52% to +14%) by 2009 
on a 1999 baseline (Lopez et al 2006). However, the same 
Table 2 Estimated COPD deaths by WHO region in 2000 
(Lopez et al 2006)
WHO region   Deaths  (000s) 
Africa A
a     52 
Africa E    65 
  Americas A    141 
  Americas B    90 
  Americas D    10 
  Southeast Asia B    100 
  Southeast Asia D    556 
  Europe A    140 
  Europe B    45 
  Europe C    76 
  Eastern Mediterranean B    15 
  Eastern Mediterranean D     80 
Western Paciﬁ  c A    21 
  Western Paciﬁ  c B  1354 
  World   2748   
aMortality strata: A, very low child/adult mortality; B, low child/adult mortality; 
C, low child and high adult mortality; D, high child and adult mortality; E, high child 
and very high adult mortality.
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Figure 1 Change in age-adjusted death rates for COPD and other leading causes 
of death in the USA from 1965 to1998. Reprinted from Pauwels RA, Rabe KF. 
2004. Burden and clinical features of chronic obstructive pulmonary disease 
(COPD). Lancet, 364:613–20. Copyright © 2004 with permission from Elsevier.International Journal of COPD 2006:1(3) 223
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analysis projects a 2% rise in COPD mortality in females 
over this period (90% credible intervals –40% to +65%), 
perhaps reﬂ  ecting the trend towards increased cigarette 
smoking in this group.
In Lithuania, mortality rates over the period 1989–1998 
decreased by 5.7% (p=0.002) in men aged 35–64 years and 
by 2.9% for men in the ≥65-year age group (p=0.001). For 
women, the decrease in mortality over this period was 7.2% 
(p=0.006) in the 35–64 years age group and 2.5% (p=0.03) 
among those aged ≥65 years, respectively (Lesauskaite 
2003). In a period when worldwide COPD mortality is 
increasing, these data indicating a decline in the rate of 
COPD mortality in Lithuania are noteworthy. Decreased 
prevalence of smoking, modernization of industry leading to 
reduced pollution in the workplace, and changes in treatment, 
including the use of long-term oxygen therapy (LTOT) and 
inhaled medications, may account for the decrease in COPD 
mortality in Lithuania.
Data from developing countries
Data on COPD mortality rates in WHO regions outside 
the USA and Europe are less abundant and, where data 
collection and record keeping are inadequate, may be less 
reliable. However, COPD is clearly a major health concern 
in developing countries and smoking-related mortality in 
general is expected to represent a particular problem in 
China, India, and the Middle East in future years, contrasting 
with predicted declines in developed countries. Using vital 
registration data provided by 112 member states, the WHO 
estimated that COPD accounted for 5.2% of all deaths in 
developing countries in 2000 (sixth leading cause of death), 
compared with 3.2% in developed countries (ﬁ  fth leading 
cause of death). 
COPD mortality rates in Asian countries are similar to, or 
in some cases markedly higher than, those in Western Europe 
and the USA. The WHO World Health Report for 2002 
estimated a COPD mortality rate of 40.0/100 000 population 
for the Southeast Asia region and 79.8/100 000 population 
for the Western Paciﬁ  c region, which includes China (Tan 
2002; WHO 2002). The estimated COPD mortality rate for 
the Americas region (including the USA and Canada) was 
26.8/100 000 population and for Africa it was 18.1/100 000 
population. Although mortality data from Latin America 
and Africa are scant, epidemiological changes, increases in 
smoking, infectious diseases, and pollution are expected to 
lead to increased COPD mortality in these regions. Recently 
published data from the Latin American Project for the 
Investigation of Obstructive Lung Disease (PLATINO) 
prevalence study may support this notion (Menezes et al 
2005). Although this study did not measure mortality, the 
relatively high prevalence rates (8%–20%) are likely to 
indicate a considerable burden of COPD mortality in this 
region. These rates are likely to be under-reported due to 
under-diagnoses of the disease.
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Figure 2 Age-adjusted COPD mortality rates in individuals aged 35–74 years in selected European countries (non-European country data are provided for comparison). 
Reprinted from Hurd SS. 2000. International efforts directed at attacking the problem of COPD. Chest, 117:S336–8. Copyright © 2000 with permission from CHEST.International Journal of COPD 2006:1(3) 224
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Gender differences in COPD mortality
Evidence suggests there may be a relationship between 
gender and COPD mortality rates. For example, global 
mortality data from the WHO World Health Report (WHO 
2002) show that COPD mortality rates were higher in men 
for almost all regions. The only exception was in the Western 
Paciﬁ  c region, where mortality in women was estimated at 
90/100 000 population compared with 70/100 000 popula-
tion in men.
A notable trend in the US COPD mortality data is 
increased mortality in women in general (with the total 
number of women dying from COPD now exceeding that 
for men) and for white women in particular. A report by the 
US Centers for Disease Control (CDC) noted that, despite 
all-cause death rates decreasing by 32% for men and 14% 
for women from 1968 to 1999, the COPD mortality rate 
over this period increased by 382% for women to 41/100 000 
population and by 27% for men to 44/100 000 population 
(Kazerouni et al 2004). The ALA report stated that 51% of 
deaths due to COPD in 2002 were in women; this was the 
third consecutive year in which deaths in women exceeded 
those in men (ALA 2004). A similar trend has also been 
observed in Canadian (Weir 2004), Spanish (Sunyer et al 
1998), and Australian women (Crockett et al 1994). This 
rise in COPD mortality in women may reﬂ  ect increased 
smoking prevalence amongst other factors (Kazerouni 
et al 2004).
In all European countries, mortality rates due to COPD 
are considerably higher in men than in women, with consider-
able differences in mortality trends from 1980 to 1990. While 
there was an increase in COPD mortality among women in 
northern European countries, including Denmark and the UK, 
decreased mortality rates have been reported for women from 
Central and Eastern European countries, including Bulgaria, 
Hungary, and Romania.
Societal burden of COPD morbidity and 
mortality
The most recent data from the GBD study indicate that 
worldwide in 2000, COPD resulted in 16.5 million years 
of life lost, almost 10 million years lived with disability, 
and 26.5 million disability-adjusted life years (Lopez et al 
2006). 
With regard to ﬁ  nancial costs, the US NHLBI Chart Book 
estimated a total cost of COPD of US$37.2 billion in the USA 
in 2004, of which direct medical costs accounted for US$20.9 
billion (NHLBI 2004). Of the indirect costs, US$7.4 billion 
was attributed to morbidity and US$8.9 billion to mortality. 
This analysis did not take into account costs for COPD as a 
secondary cause of morbidity or mortality. 
The European Lung White Book 2003, estimated the 
total annual cost of COPD in Europe at €38.7 billion 
(US$51.2 billion) with a cost for ambulatory care of 
€4.7 billion, a cost for drugs of €2.7 billion, a cost for in-
patient care of €2.9 billion (~US$5.6, 3.2, and 3.5 billion 
respectively, based on 2005 conversion rates), and a total 
of 28.5 million work days lost due to COPD. As these data 
exclude mortality costs, the actual cost incurred by COPD 
may be much higher.
In general, healthcare economics of COPD are char-
acterized by an unwillingness to attribute the cost of a life 
lost. Available data suggest that COPD presents a large and 
under-estimated mortality-related cost to healthcare systems 
and to society.
Impact of therapeutic interventions 
on COPD mortality
Clearly, the burden of COPD can be reduced by preventing 
at-risk individuals from developing the disease. This can be 
achieved by screening for COPD in susceptible people and 
involves taking detailed patient history to assess risk factor 
exposure (eg, tobacco smoke), medical and family history, 
and presence of genetic risk factors or comorbid conditions. 
Early identiﬁ  cation and prevention of COPD progression, 
eg, by reducing exposure to tobacco smoke, occupational 
substances, and air pollution, would impact positively the 
burden of COPD mortality.
Once established, a variety of effective treatments 
exists for COPD. Several studies report the impact of 
management and therapies on COPD, although survival is 
rarely the primary endpoint of such studies. Data for the 
impact of therapy on COPD survival are reviewed below, 
considering both non-pharmacological and pharmacologi-
cal options.
Non-pharmacological interventions
Smoking cessation
Smoking cessation is the single most effective way to re-
duce the risk of developing COPD (Sin and Tu 2000a) and 
the only intervention proven to slow the accelerated decline 
in lung function related to the condition (Anthonisen et al 
1994; Decramer et al 2005). However, there are few data on 
the effect of smoking cessation on COPD mortality among 
people with COPD. Follow-up of the Lung Health Study International Journal of COPD 2006:1(3) 225
Changing the burden of COPD mortality
cohort of almost 6000 smokers with asymptomatic airway 
obstruction showed that a 10-week smoking cessation 
intervention program signiﬁ  cantly reduced all-cause mor-
tality compared with usual care, with a 14-year follow-up 
(Anthonisen et al 2005). The overall mortality rate in 
the smoking cessation intervention group (n=3923) was 
8.83/1000 person-years, compared with 10.38/1000 person-
years in the usual care group (n=1 964; p=0.03). Although 
smoking cessation reduced the incidence of most causes 
of death, only the reduction in respiratory deaths was 
statistically signiﬁ  cant (Anthonisen et al 2005). The mor-
tality rate for respiratory deaths unrelated to lung cancer 
was 0.56/1000 person-years in the smoking intervention 
group and 1.08/1000 person-years in the usual care group 
(p=0.01). Interestingly, there were salutary respiratory 
beneﬁ  ts with quitting smoking at any time during the 
5-year intervention (Scanlon et al 2000; Anthonisen et al 
2005); these effects were maintained during the 11-year 
follow-up of these data and even observed in intermittent 
quitters. Certainly, in the general population smoking ces-
sation provides a survival beneﬁ  t, but that topic is beyond 
the scope of this paper.
Oxygen therapy and non-invasive positive pressure 
ventilation (NPPV)
Two landmark studies conducted during the 1980s includ-
ing a total of 290 patients with COPD and a resting mean 
PaO2 <60 mmHg demonstrated a 40% improvement in 
survival in patients given supplemental oxygen (relative 
risk [RR] for mortality = 0.61; 95% conﬁ  dence interval 
[CI]: 0.46, 0.82) (MRCWP 1981; NOTTG 1980). In the 
ﬁ  rst of these studies a signiﬁ  cant (p=0.01) improvement 
in survival was observed for patients who received con-
tinuous oxygen therapy (mean 24-month mortality rate 
22.4%) compared with those who received nocturnal 
oxygen therapy only (mean 24-month mortality rate 40.8%) 
(NOTTG 1980). 
The survival advantage for oxygen therapy is most pro-
nounced in patients with more severe disease and a greater 
degree of hypoxemia. In two further trials including a total 
of 211 patients with resting mean PaO2 ≥60 mmHg, therapy 
with supplemental oxygen did not signiﬁ  cantly affect sur-
vival (RR=1.16; 95% CI: 0.85, 1.58) (Górecka et al 1997; 
Chaouat et al 1999).
A Cochrane systematic review and meta-analysis of 
NPPV for respiratory failure following COPD exacerbation 
showed that NPPV, as an adjunct to usual care, was associ-
ated with reduced mortality (RR=0.41; 95% CI: 0.26, 0.64) 
compared with usual care alone (Lightowler et al 2003). 
A number of other studies have reported (Confalonieri et 
al 1999; Bardi et al 2000) or suggested (Jones et al 1998) 
survival beneﬁ  ts for the use of NPPV in COPD patients. 
The mechanisms responsible for the increased survival 
beneﬁ  t for oxygen therapy are unclear, but are thought 
to include improvement in pulmonary hemodynamics 
(Bergofsky 1983; Kawakami et al 1983; Petty and Bliss 
2000) and partial reversal of autonomic nervous system 
dysfunction (Scalvini et al 1999).
Lung transplantation and lung volume reduction 
surgery (LVRS)
While lung transplantation may improve the functional status 
and exercise tolerance of patients with COPD, there is no 
evidence of a survival beneﬁ  t. A study of patients listed for 
lung transplantation in the USA between 1992 and 1994 
found no signiﬁ  cant difference in 2-year survival between 
patients who received transplants and those who remained 
on a waiting list (Hosenpud et al 1998).
LVRS has been shown to prolong survival in a very 
select group of patients with severe COPD. A study of 
patients with severe emphysema (mean post-bronchodila-
tor FEV1 27% predicted) who were randomized to undergo 
LVRS (n=608) or to receive continued medical treatment 
(n=610) showed that the overall mortality rate was 0.11 
per person-year in both groups (RR for death in the surgery 
group 1.01, p=0.90) (Fishman et al 2003). However, among 
patients with predominantly upper lobe emphysema and 
low exercise capacity, mortality was lower in the surgery 
group (0.07 deaths per person-year) than in patients treated 
medically (0.15 deaths per person-year; RR for death 0.47, 
p=0.005). Conversely, for patients with non-upper lobe 
emphysema and high exercise capacity mortality was higher 
in the surgery group (0.10 deaths per person-year) than in 
medically treated patients (0.05 deaths per person-year; 
RR=2.06, p=0.02).
Pulmonary rehabilitation
Pulmonary rehabilitation programs appear to improve 
the health status and increase the exercise tolerance of 
patients with moderate-to-severe COPD, but there is little 
good evidence of a beneﬁ  cial impact on mortality. Meta-
analysis of data from eight studies investigating the use of 
pulmonary rehabilitation programs lasting from 8 weeks to 
12 months for patients with COPD indicated no signiﬁ  cant 
impact on mortality (RR=0.90; 95% CI: 0.65, 1.24) (Sin 
et al 2003).International Journal of COPD 2006:1(3) 226
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Other potential interventions
Malnutrition, weight loss, and reduced skeletal muscle mass 
are all associated with a higher mortality rate in COPD 
patients (Wilson et al 1989; Schols et al 1998; Marquis 
et al 2002). Only recently has the management of weight 
loss and muscle wasting formed part of the COPD treat-
ment strategy. The role of nutritional supplementation in 
COPD is questionable as meta-analysis of all available 
data shows that this intervention has no signiﬁ  cant affect 
on anthropometric variables, lung function, or exercise 
capacity (Ferreira et al 2005). Based on these ﬁ  ndings 
it seems unlikely that nutritional supplementation can 
reduce COPD mortality, although this has not been directly 
assessed. However, a combination of nutritional support 
and exercise can result in functional improvements, and 
patients responding to this approach have shown decreased 
mortality (Schols et al 1998). Unfortunately, these data are 
limited and more research into this area is clearly required 
(Schols 2003).
In addition, reduction in ﬁ  ne particulate air pollution has 
been linked to reduced mortality; this trend was observed 
speciﬁ  cally for deaths due to cardiovascular and respiratory 
causes, but not lung cancer (Laden et al 2006). Therefore, 
lifestyle adjustments to minimize exposure to air pollutants 
may also positively impact COPD mortality.
Pharmacological interventions
A wide range of pharmacological therapies have been 
used to treat patients with COPD. These include short-
acting bronchodilators (including β2-agonists [SABA] and 
anticholinergics), long-acting bronchodilators (including 
β2-agonists [LABA], and muscarinic antagonists [LAMA] 
such as tiotropium), inhaled corticosteroids (ICS), oral 
steroids, oral theophyllines, antibiotics, and inﬂ  uenza and 
pneumococcal vaccines.
Short-acting bronchodilators
Short-acting bronchodilators, including SABA and short-
acting anticholinergics, are commonly used to manage 
symptoms and improve exercise tolerance in patients with 
COPD, but there is no evidence of any effect of treatment 
on survival. Analysis of mortality data (149 deaths) from the 
5-year Lung Health Study (Buist 1997) showed no signiﬁ  cant 
differences between treatment groups for all-cause mortality, 
including patients treated with ipratropium (Anthonisen 
et al 2002).
Studies comparing short-acting combinations (iprat-
ropium plus albuterol or metaproterenol) with SABA or 
anticholinergic monotherapies have not shown any beneﬁ  t 
in terms of reduced mortality (Tashkin et al 1986; COMBIV-
ENT Inhalation Aerosol Study Group 1994; COMBIVENT 
Inhalation Solution Study Group 1997).
Long-acting bronchodilators
A meta-analysis (Sin et al 2003) of nine randomized, placebo-
controlled trials of LABA treatment, involving 4198 patients 
with moderate-to-severe COPD and study duration lasting 
from 12 to 52 weeks, did not show any signiﬁ  cant improve-
ment in all-cause mortality with active treatment (RR=0.76; 
95% CI: 0.39, 1.48). However, individual trials carried out to 
date are too short and under-powered to evaluate the effects 
of long-acting bronchodilators on all-cause mortality.
Inhaled corticosteroids
Data from large, randomized, controlled trials, prospec-
tively designed to assess the impact of ICS on mortality, are 
currently unavailable. However, a pooled analysis of data 
from randomized, placebo-controlled trials from the 1990s 
comparing ICS with placebo (with primary endpoints other 
than mortality) indicated a strong trend in favor of ICS im-
proving mortality versus placebo (RR for mortality = 0.78; 
95% CI: 0.58, 1.05), although statistical signiﬁ  cance was not 
reached (Table 3) (Sin et al 2003). A separate meta-analysis 
(Alsaeedi et al 2002) reviewed data from ﬁ  ve randomized, 
placebo-controlled trials of ICS in patients with COPD 
that included all-cause mortality data. Once again a non-
signiﬁ  cant trend towards improved survival in favor of ICS 
over placebo was observed (RR for mortality = 0.84; 95% 
CI: 0.60, 1.18). When two additional trials that compared 
combined therapy with ICS plus a LABA with placebo were 
included in an additional sensitivity analysis (Mahler et al 
2002; Szafranski et al 2003), a stronger trend was observed 
(RR for mortality = 0.75; 95% CI: 0.57, 1.00), but again 
statistical signiﬁ  cance was not achieved. The pooled data 
for these two studies alone showed a RR for mortality of 
0.52 (95% CI: 0.20, 1.34) for active treatment with ICS 
plus salmeterol versus placebo.
It is notable that none of the studies included in these meta-
analyses were designed with improvement in COPD survival 
as their primary aim. The Inhaled Steroids in Obstructive 
Lung Disease in Europe (ISOLDE) trial did identify a trend 
towards improved survival among COPD patients treated 
with ﬂ  uticasone proprionate (FP) (Waterhouse et al 1999). 
First analysis of data from the trial, in which 751 patients with 
moderate-to-severe COPD were randomized to 3 years’ treat-
ment with FP or placebo, indicated no survival advantage for International Journal of COPD 2006:1(3) 227
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the steroid. However, when the data were re-analyzed using 
an intent-to-treat approach (identifying deaths in patients who 
dropped out of the study and conducting a more thorough 
search of deaths via the UK Ofﬁ  ce of National Statistics), there 
was a non-signiﬁ  cant (p=0.069) trend for patients treated with 
FP to survive longer than those who received placebo.
The most recent analysis of the effect of ICS treat-
ment on COPD mortality has been provided by the Inhaled 
Steroid Effects Evaluation in COPD (ISEEC) study, with a 
pooled analysis of individual patient-level data from seven 
randomized controlled trials of at least 12 months’ dura-
tion in COPD patients with stable disease (5085 patients in 
total) (Sin et al 2005). ICS treatment signiﬁ  cantly reduced 
all-cause mortality by 27% compared with placebo (hazard 
ratio [HR]=0.73; 95% CI: 0.55, 0.96). This beneﬁ  cial effect 
was most pronounced in women (HR=0.46; 95% CI: 0.24, 
0.91), former smokers (HR=0.60; 95% CI: 0.39, 0.93), and 
patients with a baseline post-bronchodilator FEV1 <60% 
of predicted (HR=0.67; 95% CI: 0.48, 0.94). The use of 
individual patient-level data differentiates this analysis from 
previous meta-analyses that have not identiﬁ  ed a signiﬁ  cant 
survival beneﬁ  t for ICS in COPD.
Non-randomized, observational cohort studies for ICS
A number of non-randomized, observational, population-
based, cohort studies have evaluated the impact of ICS on 
COPD mortality (Table 4). In a population-based cohort 
study of data from Canadian databases on 22 620 elderly pa-
tients with COPD, patients who received ICS therapy within 
90 days of hospital discharge were 29% (95% CI: 22%, 35%) 
less likely to die during a one-year follow-up than those who 
did not receive ICS (Sin and Tu 2001). Another Canadian 
cohort study used hospital discharge data to identify 6740 
patients aged ≥65 years who had been hospitalized for COPD 
(Sin and Man 2003b). Analysis of all-cause mortality data for 
this cohort showed a 25% decrease in mortality in patients 
treated with an ICS following discharge from hospital. 
Three other large pharmaco-epidemiological studies 
have analyzed data from the UK General Practice Research 
Database (GPRD) (Soriano et al 2002, 2003; Kiri et al 
2005a). In the ﬁ  rst of these studies (Soriano et al 2002), 
newly diagnosed patients aged ≥50 years were identiﬁ  ed in 
primary care between 1990 and 1999. Three-year survival 
was signiﬁ  cantly higher in 1045 patients who received FP 
and/or salmeterol (78.6%) compared with 3620 patients who 
received no ICS or LABA (63.6%; p<0.05). After adjusting 
for confounding factors, the risk of death (compared with 
patients who received neither ICS nor LABA) was lowest 
in the patients who received concomitant therapy, followed 
by patients who received FP alone and those who received 
salmeterol alone. In the second GPRD study (Soriano et al 
2003), survival data were evaluated for 3636 patients who 
received an ICS and/or a LABA within one year of their 
ﬁ  rst hospitalization and compared with a reference group of 
627 patients who were prescribed short-acting bronchodila-
tors only. One-year mortality rates were 24.3% (reference 
group), 17.3% (LABA only), 17.1% (ICS only), and 10.5% 
(ICS plus LABA). Multivariate analysis indicated that, 
versus no treatment, the risk of re-hospitalization or death 
was reduced by 16% in patients who received ICS alone 
Table 3 Summary of data from randomized placebo-controlled clinical trials investigating the effect of pharmacotherapy on mortality 
in COPD patients
Source of data   Comparison   RR
a (95% CI) of   Statistical 
   mortality    signiﬁ  cance 
Clinical trials for ICS 
(Burge et al 2000)     FP vs placebo    0.77 (0.54, 1.11)   NS 
(Van Der Valk et al 2002)     FP vs placebo    0.98 (0.06, 15.55)   NS 
(Lung Health Study Research Group 2000)    Triamcinolone vs placebo    0.79 (0.40, 1.53)   NS 
(Vestbo et al 1999)    Budesonide vs placebo    0.80 (0.22, 2.92)   NS 
(Pauwels et al 1999)    Budesonide vs placebo    0.81 (0.22, 2.04)   NS 
Pooled summary (n=3678) (Sin et al 2003)    ICS vs placebo    0.78 (0.58, 1.05)   NS   
Pooled summary (n=5085)  (Sin et al 2005)    ICS vs placebo    0.73 (0.55, 0.96)   Signiﬁ   cant 
Clinical trials for LABA + ICS 
(Szafranski et al 2003)   Budesonide+formoterol  vs  placebo    0.66 (0.24, 1.81)   NS 
(Mahler et al 2002)    FP+salmeterol vs placebo    0.16 (0.01, 3.01)   NS 
Pooled summary (n=1486) (Sin et al 2003)   ICS+LABA  vs  placebo    0.52 (0.20, 1.34)   NS 
aHazard ratio.
Abbreviations: CI, conﬁ  dence interval; FP, ﬂ  uticasone propionate; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; NS, not signiﬁ  cant; RR, relative risk.International Journal of COPD 2006:1(3) 228
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(p<0.05) and by 41% in patients who received both ICS 
and LABA (p<0.05). In the third GPRD study (Kiri et al 
2005a), survival rates were evaluated in 437 pairs of patients 
(matched on disease severity) who either received ICS plus 
LABA or ICS plus SABA within one year of their ﬁ  rst 
hospitalization. Signiﬁ  cantly fewer patients prescribed ICS 
with LABA experienced re-hospitalization or death within 
12 months compared with those given ICS with SABA (12.1 
vs 18.1%; p<0.05). In multivariate analyses, use of ICS plus 
LABA was associated with 40% fewer deaths than use of 
ICS plus SABA (RR=0.60, 95% CI: 0.37, 0.98). As ICS are 
generally prescribed to patients with more advanced disease, 
a higher risk of mortality in these patients might be expected. 
However, these studies demonstrated a reduction in risk with 
ICS, given alone or in combination with a LABA, despite 
the expectation of poorer prognosis. 
Although such studies are valuable to show associations 
between therapeutic interventions and particular outcomes 
in real-life settings and, as such, have provided tantalizing 
evidence that ICS may have a beneﬁ  cial effect on mortality 
in COPD, not every observational study agrees with this 
contention (Fan et al 2003; Suissa 2003, 2004). Suissa, Fan 
and colleagues have criticized these studies as having been 
designed with bias (known as “immortal time bias”) which 
could lead to an overestimation of an effect of ICS. Immortal 
time bias arises when subjects cannot by deﬁ  nition incur the 
outcome event under the study (ie, death). For example, if 
a study design stipulates that a new treatment (eg, ICS) is 
added to a patient’s care at some time after an initial index 
date (ie death) then anyone dying before initiation of ICS 
would be allocated to a control group rather than the inter-
vention group. This bias might lead to an overestimation of 
the effect of an ICS.
Recently, Kiri and co-workers explored the extent to 
which immortal time bias is responsible for the beneﬁ  cial 
effects of ICS in patient’s with COPD (Kiri et al 2005b). 
Two designs free of any immortal time bias were used 
on the GPRD COPD patient data. Design one used only 
Table 4 Effect of ICS therapy on COPD mortality in non-randomized cohort studies
Source of data   Comparison    Risk of death (95% CI)   Summary  of  outcome 
(Sin and Tu 2001)    ICS vs no ICS    0.71 (0.65, 0.78)    Signiﬁ  cant survival beneﬁ  t with ICS 
(Soriano et al 2002)    FP + salmeterol vs no ICS or LABA    0.48 (0.31, 0.73)    Signiﬁ  cant survival beneﬁ  t with FP and 
     salmeterol 
    FP alone vs no ICS or LABA    0.62 (0.45, 0.85)    Signiﬁ  cant survival beneﬁ  t with FP alone 
    Salmeterol alone vs no ICS or LABA    0.79 (0.58, 1.07)    Signiﬁ  cant survival beneﬁ  t with 
     salmeterol  alone 
(Soriano et al 2003)
b    ICS + LABA   10.5%    Reduction in risk of rehospitalization or 
   ICS  alone   17.1%    death with ICS and/or LABA    
   LABA  alone   17.3%    
   SABA  alone   24.3%    
(Sin and Man 2003a)    ICS vs no ICS    0.75 (0.68, 0.82)    Signiﬁ  cant survival beneﬁ  t with ICS 
   Low-dose
a ICS vs no ICS    0.77 (0.69, 0.86)     overall, and especially for medium- to
   Medium-dose
a ICS vs no ICS    0.48 (0.37, 0.63)     high-dose ICS 
   High-dose
a ICS vs no ICS    0.55 (0.44, 0.69)    
(Suissa 2003)    ICS vs no ICS    0.69 (0.55, 0.86)  No reduction in morbidity or mortality
  Time ﬁ  xed adjusted rate      with  ICS 
  ICS vs no ICS    1.00 (0.79, 1.26)    (after controlling for time dependence)
  Time dependent rate    
(Suissa 2004)    ICS vs bronchodilators    0.66 (0.57, 0.76)    No reduction in all-cause mortality with 
     ICS 
(Fan et al 2003)    Low-dose ICS vs no ICS    0.75 (0.53, 1.05)    No reduction in mortality or 
    Medium-/high-dose ICS vs no ICS    0.91 (0.73, 1.13)     exacerbations with ICS 
(Kiri et al 2005b)    ICS vs no ICS    0.69 (0.052, 0.93)    Survival beneﬁ  t with ICS 
 propensity  scores      (in both models)
    ICS vs no ICS    0.71 (0.56, 0.90) 
  nested case control      
aDose was converted to beclomethasone equivalents and classiﬁ  ed as low (≤500 μg/day), medium (501–1000 μg/day), and high (>1000 μg/day).
bThis study reported one-year mortality rates.
Abbreviations: CI, conﬁ  dence interval; FP, ﬂ  uticasone propionate; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; NS, not signiﬁ  cant.International Journal of COPD 2006:1(3) 229
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patients whose treatment status was deﬁ  ned on the same 
day of discharge to obtain a matched cohort based on pro-
pensity scores. Design two used all patients who had died or 
been re-hospitalized and matched each case with up to four 
non-cases by randomly sampling from the cohort risk sets, 
irrespective of treatment status. From the propensity scores 
matched-cohort analysis, treatment with ICS resulted in a HR 
estimate of 0.69 (95% CI: 0.52, 0.93). The matched nested 
case-control analysis gave rate ratio estimates of 0.71 (95% 
CI: 0.56, 0.90). The authors concluded that a beneﬁ  cial as-
sociation between ICS and the risk of death/re-hospitalization 
in patients with COPD does indeed exist and is free from 
immortal time bias.
Oral steroids
Some studies have indicated that oral corticosteroids may 
have a negative impact on mortality in COPD patients. 
In a retrospective cohort study of 556 patients receiving 
oral steroids for COPD, maintenance treatment with oral 
steroids (administered without ICS) was associated with an 
increased risk of mortality (RR=2.34; 95% CI: 1.24, 4.44 
for a prednisone equivalent dose of 10 mg per day) (Schols 
et al 2001). This risk appeared to be dose-dependent and 
was almost doubled in patients who received a prednisone 
equivalent dose of 15 mg per day (RR=4.03, 95% CI: 1.99, 
8.15). However, the risk of mortality appeared to be smaller 
when oral steroids were administered with ICS and the 
use of ICS alone was associated with decreased mortality 
(RR=0.55, 95% CI: 0.43, 0.70). A retrospective study of 
403 Swedish COPD patients receiving LTOT found that 
increased mortality was associated with the use of oral 
steroids in women (RR=1.49; 95% CI: 1.00, 2.22), but not 
in men (RR=1.08; 95% CI: 0.74, 1.59) (Ström 1998). ICS 
therapy did not affect mortality in this study (RR=0.88; 
95% CI: 0.62, 1.23).
Other treatments
There are at present insufﬁ  cient data from clinical trials 
evaluating the effects of treatment with oral theophylline, 
antibiotics, or vaccines on COPD mortality. 
A retrospective cohort study of more than 26000 
Canadian patients who were hospitalized for COPD 
showed that outpatient use of antibiotics within 30 days 
before the index hospitalization was associated with a 
signiﬁ  cant reduction in mortality in the 30 days following 
hospital entry (odds ratio = 0.83; 95% CI: 0.75, 0.92) (Sin 
and Tu 2000b). The early use of antibiotics might therefore 
be considered in COPD patients who experience an acute 
exacerbation. 
Although there are no data on the impact of inﬂ  uenza 
and pneumococcal vaccines on mortality in COPD patients, 
they have been shown to reduce mortality by 30%–40% in 
the elderly (Nichol et al 2003). As many COPD patients are 
elderly and at increased risk of inﬂ  uenza and pneumonia, 
vaccination may be useful in this population.
Ongoing studies
A large, prospective, randomized placebo-controlled trial is 
clearly required to speciﬁ  cally evaluate the impact of ICS 
and LABAs, as monotherapy or in combination, on mortality 
in COPD patients and end current uncertainty on this topic. 
It is hoped that the ongoing landmark TORCH (Towards 
a Revolution in COPD Health) survival study will achieve 
this. This international, multicenter, randomized, double-
blind, placebo-controlled, parallel-group study includes 
more than 6000 patients with moderate-to-severe COPD 
from 45 countries (Vestbo and The Torch Study Group 
2004). Patients were randomized to receive three years 
of treatment with FP and salmeterol, FP alone, salmeterol 
alone, or placebo. The primary endpoint is the difference 
in all-cause mortality between combination FP and salm-
eterol therapy and placebo. The ﬁ  rst patient was recruited 
in September 2000 and results are expected in 2006. The 
ongoing UPLIFT (Understanding the Potential Long-term 
Impacts on Function with Tiotropium) study (Decramer 
et al 2004) will also report on mortality (respiratory and 
all-cause), but this study is not designed or powered to 
speciﬁ  cally investigate this endpoint. Results from this trial 
are expected in 2008.
Conclusions
COPD represents an important and growing healthcare con-
cern as a leading cause of death and disability worldwide. It 
is likely that the impact of COPD has been under-estimated 
due to a lack of accurate epidemiologic data from some 
countries, misdiagnosis, and inconsistent use of ICD codes 
when reporting causes of death in patients with COPD. 
Particularly worrying is the marked increase in deaths (in 
most, but not all countries) due to COPD over the past 
couple of decades, a trend that is predicted to continue. 
Also cause for concern is the dramatic rise in COPD mor-
tality seen in women in many countries. In addition to the 
considerable mortality and morbidity burden of COPD, this 
condition also incurs signiﬁ  cant ﬁ  nancial costs associated International Journal of COPD 2006:1(3) 230
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with the care of patients and lost productivity of patients 
and carers. Improved treatment of COPD, and the ability 
of a therapeutic intervention to improve survival, therefore 
represents an important goal.
Currently, smoking cessation is the single most effective 
intervention to improve outcomes in patients with COPD; 
however, even in the best programs less than one-third of 
patients sustain abstinence, and dyspnea and other symptoms 
may persist. Supplemental oxygen and LVRS have also been 
shown to improve survival in selected patients. With regard 
to pharmacotherapy, a growing body of evidence indicates 
that there may be a survival beneﬁ  t for treatment with ICS 
or long-acting bronchodilators. However, conclusive data 
are currently lacking so the results of ongoing studies are 
awaited with interest.
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